ABOUT ZENITAR

About us- Zenitar

  • Zenitar was established in April 2019.

  • Located in the Chengdu High-tech Zone Biomedical Incubation Park, with 4,000 m2  of scientific R&D building.

  • A biomedical enterprise in the clinical stage.

  • Finished round A financing of 100 million RMB in November 2021, and round B financing of 200 million RMB in December 2023, separately.

  • Authorized 33 international or domestic invention patents, applied for 28 patents.

Our interest and achievements

  • Focusing on oncology, autoimmunity and inflammatory diseases
    We are committed to the discovery, development and commercialization of first-in-class (FIC) and best-in-class (BIC) innovative drugs.


  • Enrichment pipeline  
    Three innovative drugs covering six indications on clinical trial phase I and phase II in China, with one having received clinical trial approval from the FDA. Additionally, there is a pipeline of over ten preclinical products in development.


  • A start-to-end innovative drug development platform

    Incorporates our proprietary artificial intelligence for molecular design, structural biology, high-throughput screening using organ-like models, pharmacology and efficacy studies with PDX models, CMC, clinical trials, regulatory filings, and more.

Founder Introduction

Lijuan Chen

Chairman/General Manager, Chief Scientist
PhD (UK)

Personal Resume:

  • 2019-Now:Founder，Chairman and Chief scientist of Chengdu Zenitar Biomedical Technology.

  • 2012-2016:Chief Scientist of Guangdong Sentient Pharmaceutical Co., LTD.

  • The third batch of innovation and entrepreneurship leader in the Guangdong Pearl River Talent Program “Cancer and diabetes research and development”.

  • 20 years of experience in new drug research and development.


Personal Honor:

  • Professor of West China Hospital, Deputy Director of the State Key Laboratory of Biotherapy.

  • Academic and technical leader of Sichuan Province.

  • Tianfu Ten Thousand Plan leading talent, Chengdu “Rong Piao plan” entrepreneur.

  • Winner of the Wuxi AppTec Prize in Life Chemistry.


Major scientific and technological achievements:

  • Leading 10 innovative drugs development from preclinical to clinical trial  including tumor, autoimmunology disease and pulmonary fibrosis, of which 7 were approved for clinical trials, 3 entered phase II and 4 entered phase I.

  • Responsible for a number of major new drug development projects from the National Ministry of Health and Science and Technology in the 11th, 12th and 13th Five-Year Plan.

  • Published over 400 papers as the corresponding author in Nat. Commun., Sci. Adv., Clin. Cancer Res., J. Med.Chem., etc.

  • Ranked in the top 2% of the world's top scientists list released by Stanford in 2021 and 2022.

  • Been authorized 60 international and domestic patents, many of which were authorized by the United States, Australia, Japan and other countries.


Management Team Technical Advisor
  • Taijin WangHead of AI-Driven Drug Design

    Ph.D.

  • Tao JiaHead of Medicinal Chemistry

    Ph.D.

  • Rui LiangHead of Clinical Operation

    Master's degree

  • Ke TanHead of Medical Statistics

    Ph.D.

  • Xiaowei ZhangHead of CMC

    Master's degree

  • Bikun YangHead of R&D Quality

    Master's degree

  • Yuxing LiaoHead of Drug Formulation

    Master's degree

  • Xiaoyan LiuHead of Pharmacology and Toxicology

    Ph.D.

  • Liangkun SunDrug Registration Manager

    Bachelor's degree

  • Fanrong WuClinical Project Manager

    Bachelor's degree

  • Dr. Ting NiuClinical PI
    Director of the Department of Hematology, Professor, and Chief Physician at West China Hospital, Sichuan University.
  • Dr. Weili ZhaoClinical PI
    Professor and PhD supervisor, Vice Dean of Shanghai Ruijin Hospital, Distinguished Young Scholar, and Changjiang Scholar. Executive Vice Director of Shanghai Blood Research Institute, and Vice Chair of the Hematology Branch of the Chinese Medical Association.
  • Dr. Yi FangClinical PI
    Professor and PhD supervisor, currently serving as the Director of the Phase I Clinical Trial Research Lab at Peking University People's Hospital.
  • Prof. Ruobing ChaoPharmaceutical Quality Research Consultant
    Professor and PhD supervisor at the West China School of Pharmacy, Sichuan University.
  • Dr. He SunGlobal Clinical PI
    Executive Council Member of the Chinese Society of Quantitative Pharmacology, Council Member of the Chinese Pharmacological Society. Professor at School of Medicine, Shanghai Jiao Tong University. Chair Professor and PhD Supervisor at China Medical University, and Visiting Professor at the University of the Pacific School of Pharmacy.
  • Prof. Shouqing TangGlobal Clinical PI
    Physician, specializing in internal medicine and oncology in both the United States and Canada, and a Fellow of the Royal College of Physicians of Canada.

Corporate Culture

Our Philosophy

Exploring the unknown
Pioneering new frontiers

Our Mission

To translate scientific breakthroughs into life-saving therapies

Our Values

Innovation
Pragmatism
Win-win collaboration

Our Aspiration

Co-creation
Shared success
Harmonious growth